GlassScriptPhysician profile
Aaron B Kaufman
NPI 1235238387
$4,143.22
in general payments reported to CMS, 2019-2025
27 companies · $439 in 2025
The $439 reported for 2025 was more than what 82% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $401 · 2020: $496 · 2021: $635 · 2022: $863 · 2023: $734 · 2024: $574 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,747.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $825.86 | 2019-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $553.83 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $413.77 | 2019-2025 | Farxiga, Breztri |
| Lilly USA, LLC | $364.21 | 2019-2025 | Mounjaro, Zepbound |
| Amarin Pharma, INC. | $268.60 | 2019-2021 | |
| Exact Sciences Corporation | $247.31 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $185.72 | 2019-2025 | Xifaxan, Trulance |
| Idorsia Pharmaceuticals US INC | $174.44 | 2022-2023 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $166.39 | 2023-2025 | Caplyta |
| Astellas Pharma US INC | $127.29 | 2024-2025 | Veozah |
| Biohaven Pharmaceuticals, INC. | $119.54 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $108.42 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $94.32 | 2020-2025 | Rexulti |
| Pfizer INC. | $71.88 | 2019-2023 | |
| Abbott Laboratories | $66.24 | 2021-2024 | Freestyle Libre 2, Eterna |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acella Pharmaceuticals, LLC | $62.25 | 2024-2025 | NP Thyroid 60 |
| Novartis Pharmaceuticals Corporation | $49.53 | 2019-2021 | |
| Amgen INC. | $46.59 | 2020 | |
| Lundbeck LLC | $29.43 | 2025 | Rexulti |
| Inspire Medical Systems, INC. | $27.32 | 2025 | Inspire |
| Angiodynamics, INC. | $24.74 | 2024 | Auryon Laser System 100-120 Vac |
| Teva Pharmaceuticals USA, INC. | $24.44 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.20 | 2022 | |
| Ferring Pharmaceuticals INC. | $19.63 | 2022 | |
| Eisai INC. | $17.11 | 2021 | |
| Avion Pharmaceuticals | $15.89 | 2024 | NP Thyroid 60 |
| Alnylam Pharmaceuticals INC. | $15.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Kaufman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.